Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 7/26/2023 (updated 3/28/2024)
Health care workforce shortages continue to persist across rural communities, while current emerging trends have made it increasingly challenging to recruit physicians and other health care professionals. HRSA shared how one rural workforce initiative, the Rural Residency Planning and Development (RRPD) Program, is increasing the rural physician pipeline. Featured RRPD grantees discussed how their programs are shaping the behavioral health workforce of the future.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.
Posted 6/7/2022 (updated 3/27/2024)
This workshop examined the behavioral health trends of children, youth, and young adults in rural communities and best practices to increase behavioral health treatment outcomes.
Posted 6/6/2022 (updated 3/27/2024)
Whether an opioid overdose death is unintentional or intentional (i.e., suicide), it can be difficult to disentangle. The suffering and hopelessness associated with addiction often lead to indifference to living or dying and to extreme risk taking. In this presentation, examples were described and presented from an opioid-specific suicide prevention training module that is part of the SafeSide Prevention learning program
Posted 6/6/2022 (updated 3/27/2024)
Presenter(s):
Mary Roary, PhD, MBA, Director of the Office of Behavioral Health Equity, Substance Abuse and Mental Health Services Administration